An initial assessment of robotic ureteral reconstruction using buccal mucosa graft indicates that it is a feasible and reproducible approach for reconstruction of complex ureteral strictures, reconstructive urologists reported at the AUA annual meeting in New Orleans.
Don't count out men who have not recovered urinary and erectile function at 12 months after radical prostatectomy.
A recent study evaluated electrical stimulation of the afferent nerves in the foot as a way of decreasing symptoms of overactive bladder.
Researchers recently presented 12-month follow-up data from a prospective, multicenter trial of a device for sacral neuromodulation.
In other personnel news, Thomas Jefferson’s Sidney Kimmel Cancer Center has a new director and LUGPA has its first CEO.
This slideshow presents a case study of a 30-year-old male with discomfort in left groin region due to mass/swelling for 1 year.
The Sonablate 450, SonaCare Medical’s high-intensity focused ultrasound (HIFU) device, has received FDA clearance for prostate tissue ablation.
Exclusive data from our State of the Specialty survey reveals the growing importance of non-physician providers in the urology work force.
Work-related risks for bladder cancer are on the rise, but the occupations putting workers at risk seem to be evolving, according to a meta-analysis published online in JAMA Oncology (Oct. 8, 2015).
Urology Times State of the Specialty Survey 2015
Study findings point to “a concept that has haunted clinical trialists for years,” says one expert.
An immune checkpoint inhibitor provides “a real opportunity to change clinical practice” for patients with metastatic renal cell carcinoma, a study author says.
New study findings from the Ronald Reagan UCLA Medical Center, Los Angeles add evidence supporting the potential for targeted magnetic resonance-ultrasound (MR-US) fusion biopsy to improve the diagnosis of prostate cancer. Learn more
Shock wave therapy has now been subjected to multiple randomized, placebo-controlled, and additional open-label studies in clinics worldwide, demonstrating impressive efficacy and safety.
In this case, the man currently has no evidence of metastatic disease or other long-term injury from his claimed negligence that the physicians allowed the cancer to become extracapsular during the 6 months of following his PSA levels.
In our review of hundreds of charts from multiple EHR systems, several frequently made errors emerged, and for this article, we will discuss seven common mistakes end how to avoid them.
In this article and several to follow, I will discuss privacy and information security concerns and what you can do to protect your patients’ data.
In this interview, Peter L. Choyke, MD, discusses current methods of detecting biochemical recurrence with imaging, promising new techniques to localize recurrence, and cost considerations.
With the U.S. now spending nearly 18% of its gross domestic product on health care, Congress has targeted for drastic budget cuts the one agency of the government whose sole purpose is to improve the health care system.
There are many ways you can hold title to real property, which is defined as land and anything built on it. However, the way in which real property is titled will affect how it is transferred during the administration of an estate. Learn more
Phase II study results show that daily treatment with abiraterone acetate (ZYTIGA), 1,000 mg, plus prednisone, 5 mg was very effective in lowering PSA levels in men with non-metastatic castrate-resistant prostate cancer (CRPC) at high risk for metastasis. Learn more
Positron emission tomography with a 68Gallium-labeled ligand of prostate-specific membrane antigen (68Ga-HBED-PSMA-PET hybrid imaging) is a promising new diagnostic tool for staging prostate cancer, according to German urologists who presented their experience at the American Society of Clinical Oncology annual meeting in Chicago. Get results
Experience with low-intensity extracorporeal shock wave therapy from multinational clinical trials demonstrates it is a safe, effective, and well-tolerated treatment for erectile dysfunction, including in men who do not respond to an oral phosphodiesterase type-5 inhibitor, reported Robert Feldman, MD, at the AUA annual meeting in New Orleans.
Researchers have recently made progress in understanding a fundamental signaling cascade, the Programmed Death 1 (PD-1) receptor-ligand pathway,1 which holds long-awaited promise in bladder cancer intervention.
"I don’t think the CVS action will damage Viagra that much. They’ll find a way to get it to the market. It might even put some price pressure on Viagra, which could actually be a good thing," one urologist said.
“Value” is more than a buzzword in medicine. It’s the way of medicine’s world. Understanding just what it means and how to achieve it could make or break urology and other specialties.
Brian Howard Eisner, MD, examined antibiotic use in ureteroscopy and PCNL in two studies presented at the AUA annual meeting in New Orleans. He discusses the studies’ findings with Urology Times.
Hear and get results from Neal Shore, MD, as he discusses with Crystal Murcia, PhD the surveys findings, explains why men aren’t speaking up about their prostate cancer symptoms, and urologists' role in assessing how patients are feeling.
Leaders of more than 30 organizations representing urologists and scores more attendees came away from the 2015 AACU state advocacy conference with a better understanding of the complicated socioeconomic issues facing the profession and a resolve to not stand idly by as public policies impacting their patients and practice are developed in Washington and state houses across the country. Learn more.
As my practice worked through the meaningful use attestation process earlier this year, I began to believe that the government was putting us through the electronic equivalent of an aerial acrobatic maneuver that would impress Ethan Hunt of “Mission: Impossible” fame. And I wasn’t pleased.
